MetaCap

Gain Therapeutics Inc. (GANX)

NASDAQ: GANXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.9994-0.0506 (-4.82%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

GANX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$44.50M
EPS (TTM)
-$0.42
52-week range
0.94 – 4.34
Day range
0.9701 – 1.10
Volume / Avg
559.73K / 550.22K
Beta
—

52-week range

$0.94$4.34

GANX stock today

On Nov 20, GANX ended the session at $0.9994, shedding $0.0506 (4.82%), versus the S&P 500's 3.70% decline. At this level, GANX sits near the bottom of its 52-week range of $0.94 to $4.34: 77.0% below the high, set on Dec 11, 2025 and 6.3% above the low. GANX is down 69.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 62.4%.

Gain Therapeutics has posted a net loss over the last twelve months (EPS of -$0.42), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Gain Therapeutics

Company profile

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Gene Mack M.B.A.
Headquarters
Bethesda, MD
Employees
20
IPO year
2021

Financial highlights

Full financials

Gain Therapeutics reported a net loss of $20.2 million, compared with a loss of $20.4 million a year earlier. Diluted earnings per share came in at -$0.61.

Gain Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue——$55.18K$140.11K$164.99K
Growth——-60.62%-15.08%+471.29%
Net income$-20.16M$-20.41M$-22.27M$-17.59M$-13.89M
EPS (diluted)$-0.61$-0.89$-1.71$-1.48$-1.37

Analyst forecast

Forecast

Consensus (5 analysts)

strong_buy

Avg. price target

$7.20+620.43%

  • Strong buy 1
  • Buy 4
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $5.00High $8.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 11, 2026
EPS actual vs est.
$-0.07 vs $-0.13
Surprise
+46.15%

GANX news

All GANX news

Gain Therapeutics peers

Health Care sector
GANX peer companies
CompanyPrice% ChgMarket capCompare
QUCYQuantum Cyber N.V.0.512-7.25%$44.67Mvs GANX
ANVSAnnovis Bio Inc.0.7113-4.96%$44.12Mvs GANX
APLMApollomics Inc. Class A15.54-6.92%$45.28Mvs GANX
RNXTRenovoRx Inc.0.942-10.29%$45.45Mvs GANX
RLYBRallybio Corporation15.47-0.32%$43.32Mvs GANX
SPROSpero Therapeutics Inc.0.742-10.20%$43.23Mvs GANX
HOWLWerewolf Therapeutics Inc.0.9466-3.97%$46.00Mvs GANX
MISTMilestone Pharmaceuticals Inc.0.3711-7.06%$46.20Mvs GANX

Indexes, lists and sector

Gain Therapeutics stock FAQ

What is Gain Therapeutics's stock price today?

GANX last traded at $0.9994 as of Nov 20, 4:00 PM EST, down 4.82% on the day. Prices are delayed at least 15 minutes.

Who is Gain Therapeutics's CEO?

Mr. Gene Mack M.B.A. is the chief executive officer of Gain Therapeutics Inc., which has about 20 employees.

What is the GANX 52-week high?

The 52-week high for GANX is $4.34 and the 52-week low is $0.94. The stock is currently 77.0% below its high.

Compare GANX